The trajectory of Sildenafil presents a complex picture for investors. While the initial launch generated massive returns, the lapse of its exclusive rights opened the avenue to cheaper competitors, dramatically https://royalbookmarking.com/story21609090/sildenafil-and-big-pharma-a-risky-bet